系统性硬化症清髓性造血干细胞移植后自身抗体谱的特征分析
本研究利用含221种蛋白抗原的微珠芯片,对SCOT试验中接受造血干细胞移植(HSCT)或环磷酰胺(CTX)治疗的系统性硬化症患者血清IgG自身抗体进行谱分析。第26个月时两组间针对2种病毒抗原和6种自身蛋白的抗体存在显著差异;HSCT组部分患者抗体谱随时间变化。基线时20种独特抗原的自身抗体水平在无事件生存至第54个月的患者中显著更高,提示HSCT可能有利地改变自身抗体谱。
要点
- 第26个月时HSCT组与CTX组间针对2种病毒抗原和6种自身蛋白的抗体存在显著差异。
- HSCT组32例中8例、CTX组31例中1例的血清抗体谱随时间变化。
- 基线时20种独特抗原的自身抗体水平在无事件生存至第54个月的患者中显著更高。
核心结论
- 结果提示HSCT有利地改变自身抗体谱,而CTX治疗患者的自身抗体谱几乎未变。
- 尽管识别分泌蛋白的抗体通常被认为具有致病性,结果提示一个亚群可能潜在调节硬皮病中的HSCT。
研究设计与样本
- 本研究为SCOT临床试验的自身抗体谱分析,使用含221种蛋白抗原的微珠芯片检测血清IgG自身抗体。
- 第26个月比较时HSCT组23例、CTX组22例;HSCT组共32例、CTX组共31例参与者。
主要发现
- 第26个月比较显示,针对2种病毒抗原和6种自身蛋白(SSB/La、CX3CL1、甘氨酰-tRNA合成酶(EJ)、胃壁细胞抗原、杀菌/通透性增加蛋白和表皮生长因子受体(EGFR))的抗体在治疗组间显著不同。
- 线性混合模型分析发现,HSCT治疗患者中乙肝表面抗原、CCL3和EGFR的抗体水平随时间升高。
- HSCT组32例中8例、CTX组31例中1例对14种抗原中的一种或多种呈现随时间变化的血清抗体谱。
- 基线时针对20种独特抗原的自身抗体水平在无事件生存至第54个月的患者中显著更高,包括9种分泌蛋白(白细胞介素、IL-18、IL-22、IL-23和IL-27)、干扰素-α2A、干细胞因子、转化生长因子-β、巨噬细胞集落刺激因子和巨噬细胞迁移抑制因子。
关键数值与推荐
- 第26个月时HSCT组(n=23)与CTX组(n=22)间针对2种病毒抗原和6种自身蛋白的抗体存在显著差异。
- HSCT组32例中8例、CTX组31例中1例的血清抗体谱随时间变化。
- 基线时20种独特抗原的自身抗体水平在无事件生存至第54个月的患者中显著更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objective of this study was to test the hypothesis that transplantation stabilises the autoantibody repertoire in patients with favourable clinical outcomes. METHODS: We used a bead-based array containing 221 protein antigens to profile serum IgG autoantibodies in participants of the SCOT trial. RESULTS: Comparison of autoantibody profiles at month 26 (n=23 HSCT; n=22 CTX) revealed antibodies against two viral antigens and six self-proteins (SSB/La, CX3CL1, glycyl-tRNA synthetase (EJ), parietal cell antigen, bactericidal permeability-increasing protein and epidermal growth factor receptor (EGFR)) that were significantly different between treatment groups. Linear mixed model analysis identified temporal increases in antibody levels for hepatitis B surface antigen, CCL3 and EGFR in HSCT-treated patients. Eight of 32 HSCT-treated participants and one of 31 CTX-treated participants had temporally varying serum antibody profiles for one or more of 14 antigens. Baseline autoantibody levels against 20 unique antigens, including 9 secreted proteins (interleukins, IL-18, IL-22, IL-23 and IL-27), interferon-α2A, stem cell factor, transforming growth factor-β, macrophage colony-stimulating factor and macrophage migration inhibitory factor were significantly higher in patients who survived event-free to month 54. CONCLUSIONS: Our results suggest that HSCT favourably alters the autoantibody repertoire, which remains virtually unchanged in CTX-treated patients. Although antibodies recognising secreted proteins are generally thought to be pathogenic, our results suggest a subset could potentially modulate HSCT in scleroderma.
引用
- Ayoglu B, Donato M, Furst DE, et al. Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation. Ann Rheum Dis. 2023. PMID: 36653124. doi:10.1136/ard-2021-221926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。